Download the slides

---

Related articles:

• DTG + 2 NRTI
  • STRIIVING
  • NEAT22
• DTG + 3TC
  • ASPIRE

---

Table of contents

Switch to DTG-containing regimen
ASPIRE Study: switch to DTG + 3TC
Original article : Taiwo BO. Clin Infect Dis. 2017 Dec 26 (ePub ahead of print)
Dernière mise à jour : 22/12/2017

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

Design

Objective

• Primary Endpoint: proportion with treatment failure (virologic failure, loss to follow-up, discontinuation/modification of treatment) at W24
  • Virologic failure: confirmed HIV RNA > 50 c/mL
  • Non-inferiority of DTG + 3TC (margin of 12%, 80% power)

Baseline characteristics and disposition

• One confirmed virologic failure (DTG + 3TC arm)
  • HIV RNA (c/mL): W4: 21 ; W12: 48 ; W24: 375 confirmed at 235 ; W36 (on ABC/3TC + DRV/r): 264 ; W48: 85
  • At virologic failure (W24): no resistance mutation on RT or integrase ; therapeutic plasma concentration of DTG (3115 ng/mL)
• One discontinuation for adverse event (DTG + 3TC arm): constipation grade 2

Back to Table of Contents